Asset
NIVOLUMAB
Barinthus Biotherapeutics plc American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05343481 | phase2 | completed | 2022-09-21 | 2026-01-13 | Barinthus Biotherapeutics | Efficacy of VTP-300 in Chronic Hepatitis B Infection |
| NCT04778904 | phase1_2 | completed | 2020-12-22 | 2023-02-24 | Barinthus Biotherapeutics | First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV |
FDA applications (0)
This company has no applications containing this asset.